New drug combo shows promise in shrinking liver tumors before surgery
NCT ID NCT07014150
First seen May 07, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study tests whether giving a combination of two immunotherapy drugs (iIparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) before surgery can help shrink liver cancer and lower the chance of it coming back. About 33 adults with resectable liver cancer at high risk of recurrence will receive the drugs for 9 weeks before surgery. Researchers will monitor how well the tumors respond and track any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA RESECTABLE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences，Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.